Extension study for HER2 amplified advanced solid tumors (JUPITER ES)

An Extension study of trastuzumab and pertuzumab comination therapy for HER2 amplified advanced solid tumors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031220444

Enrollment

Registered

2022-11-11

Start date

2022-12-26

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors HER2, solid tumor

Interventions

Trastuzumab (loading dose: 8mg/kg, maintenance dose: 6mg/kg every 3 weeks) Pertuzumab (loading dose:840mg, maintenance dose: 420mg every 3 weeks)

D007262

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients enrolled in the Phase II study and continuing on study treatment at the time of obtaining consent for this study. (2) Women of child-bearing potential and partners of child-bearing potentail must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for 28 weeks following completion of study therapy. (3) Patients signed informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients who participated in clinical studies other than the Phase II trials within 4 weeks prior to obtaining consent for this study. (2) Patients who have a clinically significant medical condition that makes participation in this study inadvisable or makes compliance with the requirements of this study difficult. (3) Any other patients who are regarded as inappropriate for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Safety	—

Contacts

Public ContactSadakatsu Ikeda

Institute of Science Tokyo Hospital

ikeda.canc@tmd.ac.jp+81-3-5803-4873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026